Cetuximab

▎药明康德内容团队编辑 根据药明康德内容部统计，截至2024年10月28日，今年10月全球生物医药领域共计完成175起融资活动，累计公开披露的融资总额已经超过了50亿美元。其中，有28家专注于开发创新药的公司完成的单笔融资额突破了5000万美元大关。这些公司不仅涵盖了传统的小分子药物研发，也包括了多种创新的新分子疗法领域。在接下来的内容中，我们将依据公开资料为读者详细介绍其中9家获得大额融资的创新药开发公司，探讨它们所开发的创新疗法以及这些疗法未来可能带来的患者福祉。 ▲长按识别上方二维码，申请获取《2024年10月全球5000万美元以上融资事件盘点》 Triveni Bio：抗体药物研发公司 10月2日，Triveni Bio宣布完成1.15亿美元B轮融资，此轮融资将用于推动该公司管线药物的开发，包括它的主要候选药物TRIV-509，该药计划于2025年第一季度提交新药临床试验申请。此外，双特异性抗体项目TRIV-573也在持续推进中。Triveni Bio还将扩展其数据科学平台，以更精准的方式应对皮肤病及炎症性疾病，并加强其领导团队。 本轮融资由Goldman Sachs Alternatives领投，新投资者富达（Fidelity Management & Research Company）和Deep Track Capital以及A轮投资者Atlas Venture、鱼鹰资管（Cormorant Asset Management）、奥博资本（OrbiMed）、Viking Global Investors和Invus也积极参与了本轮融资。 Triveni Bio是一家生物技术公司，通过融合人类遗传学、潜在“best-in-class”抗体设计和精准医学方法致力于功能性抗体药物的研发。公司先导抗体项目（TRIV-509）能靶向激肽释放酶5和7（KLK5/7），从而治疗特应性皮炎、哮喘、其他免疫学及炎症（I&I）适应症。 公司的现任首席执行官是Vishal Patel博士，他曾担任Flagship Pioneering公司的投资组合战略与联盟主管，拥有与创业科学家和运营领导团队合作、指导科学和业务战略的丰富经验。 Resolution Therapeutics：巨噬细胞疗法开发公司 10月3日，Resolution Therapeutics宣布完成6350万英镑的B轮融资，此次融资由Syncona领投。融资所得资金主要将用于推进其在研主打项目巨噬细胞疗法RTX001进入1/2期临床试验，用于治疗终末期肝病患者。所得款项的其他用途包括投资公司的生产平台，和将其管线扩展到其他炎症和纤维化适应症，包括移植物抗宿主病（GVHD）和肺纤维化。 Resolution Therapeutics是一家处于临床阶段的生物医药公司，致力于发掘巨噬细胞疗法在治疗炎症和纤维化疾病方面的潜力。其主打项目RTX001是一款潜在“first-in-class”的工程化自体巨噬细胞疗法，旨在为终末期肝病患者提供更强的抗纤维化和抗炎作用。该疗法采用已知在巨噬细胞中表达的独特基因组合设计，以增强肝脏的再生能力，从而实现卓越的疗效和持久性。RTX001的临床开发项目目前包括两项临床研究。进行中的OPAL研究是一项多中心自然史研究，研究对象为因肝功能失代偿而首次住院的肝硬化患者。OPAL研究的目的是生成有关疾病进展轨迹的新数据，以作为EMERALD研究的对照组。1/2期EMERALD研究是一项RTX001在终末期肝病患者中的“first-in-human”开放标签研究，该试验的主要疗效终点为患者发生的临床事件。EMERALD研究已获得英国药品和健康产品管理局（MHRA）的临床试验授权，预计将于2024年第四季度开始招募患者。 公司的现任首席执行官是Amir Hefni博士，他在医药行业积累了丰富的经验，对药物研发、市场战略以及运营管理有着深刻的见解。在加入Resolution公司之前，他曾在多家知名药企担任重要职位，包括诺华（Novartis）、益普生（Ipsen）和百时美施贵宝（Bristol Myers Squibb）。 Judo Bio：小干扰RNA（siRNA）偶联药物研发公司 10月7日，Judo Bio公司宣布成立并在种子轮和A轮融资中成功筹集了1亿美元。融资所得资金将用于将公司的主导配体-siRNA共轭物项目推向临床，并进一步建立公司专有的STRIKE（选择性靶向RNA进入肾脏）平台。 Judo Bio公司主要由Atlas Venture创办并孵化，The Column Group也参与了种子轮融资。A轮融资于近期完成，由Atlas Venture、TCG和Droia Ventures共同领投，Digitalis Ventures、Euclidean Capital、Alexandria Venture Investments、YK Bioventures和其他未披露的基金参投。 Judo Bio是一家致力于向肾脏输送寡核苷酸药物的生物技术公司，其最初的管线项目是megalin-STRIKERs，该项目利用megalin受体家族选择性地向肾脏近端小管上皮细胞递送siRNA治疗药物。这些megalin-STRIKERs分子旨在沉默mRNA，从而减少特定的溶质载体蛋白（SLCs）。SLCs有助于维持循环物质的平衡，靶向SLCs是治疗各种系统性疾病的既定方法。 公司现任首席执行官是Rajiv Patni博士。Patni博士在医药和生物技术行业中拥有25年的丰富经验。此前，他曾在医药公司和几家成功上市的生物技术公司担任首席医疗官等高级职位。在任职期间，Patni博士带领团队完成了药物批准、适应症扩展和收购等一系列工作。 City Therapeutics：RNAi疗法研发公司 10月8日，City Therapeutics正式亮相，并宣布完成由ARCH Venture Partners领投的1.35亿美元A轮融资。Fidelity Management & Research Company、Invus、Slate Path Capital、Rock Springs Capital、Regeneron Ventures、AN Ventures和其他未披露的投资者也参与了本轮融资。 City Therapeutics致力于利用siRNA的新一代工程技术，建立一个强大和可持续的产品引擎，扩大基于RNAi的药物的治疗范围。公司将推进siRNA的设计、递送和靶向，以提高效力和特异性，更广泛地进入更多的组织类型，扩大在多个治疗领域的机会。当前，该公司正在建立一条创新RNAi疗法的管线，其主导项目预计将于2025年底或其前后进入临床开发阶段。 John Maraganore博士目前担任City Therapeutics的董事会执行主席，他也是该公司的联合创始人之一。在加入City Therapeutics之前，Maraganore博士曾在Alnylam Pharmaceuticals担任创始首席执行官和董事，领导该公司近20年。在他的领导下，Alnylam公司已发展成为一个全球领先的RNAi药物公司，成功实现了五种RNAi药物的全球批准和商业化。在Alnylam公司之前，Maraganore博士还在多家医药公司担任过高级领导职务，积累了丰富的行业经验和管理能力。 Purespring Therapeutics：肾病基因治疗研发公司 10月9日，Purespring Therapeutics宣布完成1.05亿美元的B轮融资，所募集的资金将用于推进其基于腺相关病毒（AVV）的基因疗法产品管线以治疗肾脏疾病，包括启动针对IgA肾病（IgAN）的1/2期临床试验。本轮超额认购由Sofinnova Partners领投，Gilde Healthcare、Forbion、British Patient Capital和创始投资者Syncona Limited也参与其中。 Purespring Therapeutics是一家致力于改变肾脏疾病治疗方法的基因治疗先驱公司，公司目前正在通过其专有的AAV基因治疗平台开发一系列治疗肾脏疾病的项目，其中包括针对IgAN和其他补体介导的肾脏疾病开发的项目PS-002、针对肾病综合征的项目以及一个未公开的肾小球肾病项目。新闻稿指出，该公司是首个利用AAV基因疗法，在肾病模型中成功直接靶向足细胞（podocyte）的公司。足细胞在约60%的肾病中受到影响，该公司的技术平台能够将转基因高效特异性递送到足细胞中，为多种肾病提供了一种具有差异性的治疗模式。 Julian Hanak先生是Purespring Therapeutics的首席执行官，拥有超过25年的生物技术和生物医药领域经验。他曾在许多医药公司担任高级领导职务，积累了丰富的基因治疗药物开发、生产和业务拓展经验。 CAMP4 Therapeutics：寡核苷酸药物研发公司 10月10日，CAMP4 Therapeutics宣布登陆纳斯达克，预计通过此次公开募股将获得约7500万美元的总收益。 CAMP4 Therapeutics是一家处于临床阶段的生物技术公司，旨在利用可编程反义寡核苷酸（ASO）药物扩增mRNA，来治疗相关疾病。该公司专有的RAP平台能够定位调节RNA（regRNA）并生成治疗候选药物，旨在靶向与单倍体不足和隐性部分功能丧失病症相关基因相关的regRNA，治疗代谢和中枢系统相关疾病。 目前，CAMP4 Therapeutics的产品管线包括针对尿素循环障碍的ASO药物CMP-CPS-001和针对SYNGAP1相关疾病的CMP-SYNGAP。此外，公司还拥有多个处于早期开发和发现阶段的项目，涵盖代谢性中枢神经系统疾病和心血管疾病。 CMP-CPS-001目前正在健康志愿者中进行1期临床试验评估。今年9月，该药物获得了美国FDA的孤儿药资格认定，此前还获得了罕见儿科疾病资格。另一个项目CMP-SYNGAP目前正在进行临床前开发，旨在治疗与SYNGAP1基因突变相关的一组中枢神经系统疾病。 Josh Mandel-Brehm先生是CAMP4 Therapeutics的总裁兼首席执行官，他拥有深厚的行业经验和卓越的领导能力。在加入CAMP4 Therapeutics之前，他在Polaris Partners担任创业合伙人，他的职业生涯还包括在多家生物技术公司担任关键的业务拓展和运营领导角色。在渤健（Biogen）工作期间，Mandel-Brehm先生在业务发展部门担任要职，负责领导和执行多项战略性活动和交易。在加入渤健之前，他在Genzyme公司罕见病业务部门的业务开发组工作。Mandel-Brehm先生的丰富经验和在生物技术行业的成功记录，使他成为CAMP4 Therapeutics的掌舵人。 AvenCell Therapeutics：CAR-T细胞疗法研发公司 10月22日，AvenCell Therapeutics宣布完成1.12亿美元的B轮融资。本轮融资由生命科学投资机构Novo Holdings领投，新投资者F-Prime Capital、Eight Roads Ventures Japan、Piper Heartland Healthcare Capital和NYBC Ventures参与了此次融资，创始投资者Blackstone Life Sciences也参与该轮融资。 此次融资所获得的资金将用于继续验证AvenCell的专有可控通用CAR-T细胞疗法平台，该平台产生的CAR-T细胞即使在患者接受治疗后也可以快速“关闭”和“打开”。与传统细胞疗法相比，该通用平台旨在更安全、更有效地治疗多种血液系统恶性肿瘤。 AvenCell Therapeutics是一家专注于推进可控的自体和异体CAR-T细胞疗法的公司。目前，AvenCell的临床管线包括一种高度差异化的自体CAR-T细胞疗法AVC-101，和一种通过CRISPR改造的异体CAR-T细胞疗法AVC-201，这两种管线均靶向急性髓系白血病（AML）细胞上常见的CD123抗原。进行中的试验正在研究这两种在研疗法用于治疗复发/难治性AML的作用，这种疾病具有很高的未竟医疗需求，且患者的治疗选择非常有限。AVC-101和AVC-201已在早期临床试验中显示出令人鼓舞的安全性和疗效。此外，AvenCell有多个管线候选药物将在未来两年进入临床阶段。 Andrew Schiermeier博士目前担任AvenCell公司首席执行官，他拥有超过二十年的生物技术和医药行业高管经验，涵盖了从管理初创公司运营到指导全球品牌战略扩张。他曾在Intellia Therapeutics担任五年领导职务，在此之前，他在德国默克（Merck KGaA）担任高级副总裁兼肿瘤学业务全球负责人，负责重建肿瘤学产品线并推动Erbitux的适应症扩展、以及全球首款商业化血液活检产品的开发上市。他还曾任Aura Biosciences、Medicine in Need Corporation（MEND）和Lantibio等公司的高管职位，积累了丰富的战略规划和执行经验。 Be Biopharma：B细胞药物开发公司 10月22日，Be Biopharma宣布已完成8200万美元的融资，此轮融资得到了多家风险投资公司和医药公司的支持，包括ARCH Venture Partners、Atlas Venture、RA Capital Management、Alta Partners、Longwood Fund、百时美施贵宝和武田创投。获得资金将用于实现该公司主打项目BE-101的临床概念验证，并推进BE-102的开发。 Be Biopharma是一家致力于发现和开发工程B细胞药物（BCMs）的公司，拥有一个强大且高效的B细胞药物平台，该平台利用基因编辑技术改造B细胞，使其能够持续产生治疗性蛋白质，最终开发出具有持久性、可滴定且可重复给药的候选药物，无需预处理，具有成为潜在“best-in-class”基因疗法的潜力。该公司管线中包含两个主要项目：用于治疗血友病B的BE-101，以及用于治疗低磷酸酶症（HPP）的BE-102。目前，BE-101已进入临床试验阶段。 Joanne Smith-Farrell博士现任Be Biopharma首席执行官，她拥有深厚的医药行业高级管理经验。在加入Be Biopharma之前，她在bluebird bio担任要职，包括首席运营官和肿瘤学业务部主管，并在辉瑞（Pfizer）、德国默克等知名药企担任高级管理职位。 Alpha-9 Oncology：癌症放射性药物研发公司 10月23日，Alpha-9 Oncology宣布成功完成超额认购的1.75亿美元C轮融资，以支持其研发管线的推进。此次C轮融资将用于支持临床阶段候选疗法的人体研究，并推动发现阶段候选药物进入临床开发。此外，还将用于扩大公司的研发能力，并持续投资于化学、生产与控制（CMC）和供应链。 此次融资由Lightspeed Venture Partners和Ascenta Capital领投。除现有投资者Frazier Life Sciences、Longitude Capital、Nextech Invest、BVF Partners和Samsara BioCapital之外，General Catalyst、a16z Bio + Health、RA Capital Management、Janus Henderson Investors、Delos Capital、Digitalis Ventures、Lumira Ventures和abrdn等新投资者也参与其中。 Alpha-9 Oncology是一家处于临床阶段的公司，致力于开发放射性药物，以切实改善癌症患者的治疗。该公司拥有一套独特的结合子、连接子、螯合剂和放射性同位素技术，这些元素在放射性药物开发中都起到关键作用。Alpha-9 Oncology对每种放射性药物的每个组成部分都进行了优化，以确保药物的选择性、稳定性和有效的载荷递送。目前，Alpha-9 Oncology已建立了一个多元化的临床期和发现阶段研发管线，涵盖经过验证的靶点和创新靶点。 David Hirsch博士目前担任公司的首席执行官。在加入Alpha-9之前，他在Longitude Capital担任风险合伙人，期间他在10多家生物技术公司的董事会任职，为这些公司的发展战略和运营决策提供了指导和支持。此前，Hirsch博士在Pequot Ventures担任过副总裁。这些经历为他积累了丰富的行业知识和管理经验。 限于篇幅，本文无法对所有公司进行介绍，若欲获取完整公司信息，请扫描或长按以下二维码，申请获取《2024年10月全球5000万美元以上融资事件盘点》。 ▲长按识别上方二维码，申请获取《2024年10月全球5000万美元以上融资事件盘点》 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料： [1] 各公司官网 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Anti-tumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025 Appointed Paige Mahaney, Ph.D. as Chief Scientific Officer Bringing More than 25 Years of Pharmaceutical and Biotech Experience Cash, Cash Equivalents and Marketable Securities of $284.4 million as of September 30, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial results today for the third quarter ended September 30, 2024, as well as recent business highlights. “2024 has been a successful year for C4T marked by strong execution across our entire portfolio, which has continued to position us as a leader in targeted protein degradation science. We recently shared initial clinical data on CFT1946 demonstrating a well-tolerated safety profile and evidence of monotherapy anti-tumor activity in BRAF inhibitor exposed patients, and we delivered our second development candidate to Biogen,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We look forward to continuing this momentum with cemsidomide Phase 1 data in multiple myeloma and in non-Hodgkin’s lymphoma being presented at ASH, and multiple CFT1946 data readouts expected in 2025. Our continued focus on discovery research, clinical development and collaborations sets us up for an exciting future and for the potential to improve patients’ lives.” THIRD QUARTER 2024 AND RECENT ACHIEVEMENTS Cemsidomide: Cemsidomide is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkin’s lymphoma (NHL). Advanced the Phase 1/2 Clinical Trial. The cemsidomide Phase 1/2 trial in combination with dexamethasone for R/R MM and as a monotherapy for R/R NHL continues to enroll patients. Dose escalation continues as the maximum tolerated dose has not yet been reached. For the combination with dexamethasone MM arm, patients are now enrolling at dose level 6 (100 µg once daily (QD)) and enrollment in the dose level 5 (75 µg QD) expansion cohort is complete. The monotherapy NHL arm continues to progress and dose level 5 (100 µg QD) is the highest dose level evaluated to date. CFT1946: CFT1946 is an oral degrader targeting BRAF V600 mutations for the potential treatment of solid tumors including colorectal cancer (CRC), melanoma and non-small cell lung cancer (NSCLC). Presented New Preclinical Data at the 7th Annual Targeted Protein Degradation (TPD) Summit: In October 2024, C4T shared new in vivo data for CFT1946 describing Kpu,u (range: 0.34 - 0.88), experimentally determined using independent methods in two different species. These results demonstrate CFT1946’s ability to cross the blood brain barrier and highlight the potential for activity in primary and metastatic central nervous system (CNS) disease.Presented Monotherapy Clinical Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept from the Ongoing CFT1946 Phase 1 Trial at the European Society for Medical Oncology (ESMO) Congress 2024: CFT1946 demonstrated a well-tolerated safety profile and evidence of monotherapy anti-tumor activity, which supports further clinical development as monotherapy and in combination with MEK and EGFR targeted therapies.Advanced the Phase 1/2 Clinical Trial. The CFT1946 Phase 1/2 trial for BRAF V600 mutant solid tumors continues to enroll patients across multiple arms of the trial: CFT1946 Monotherapy Dose Escalation in BRAF V600 Mutant Solid Tumors: Patients continue to enroll in the 640 mg twice daily (BID) pharmacodynamic (PD) backfill cohort.CFT1946 Monotherapy Melanoma Expansion Cohorts: Enrollment at the 320 mg BID dose level is complete and patients are enrolling at the 640 mg BID dose level.CFT1946 with Cetuximab Phase 1b Dose Escalation for CRC: The 160 mg BID dose level has been declared safe and patients are enrolling at the 320 mg BID dose level. RESEARCH UPDATES: Presented at the 7th Annual TPD Summit Highlighting C4T’s TORPEDO® Platform: In October 2024, at the 7th Annual TPD Summit, C4T presented kinetics-based pharmacokinetic (PK) and PD models, demonstrating the company’s ability to predict clinical PD responses across target classes. COLLABORATIONS: Delivered Second Development Candidate to Biogen. In September 2024, C4T earned an additional $8 million milestone payment after Biogen accepted delivery of a second development candidate in an undisclosed indication. Biogen is responsible for all future clinical development and commercialization for this program. This marks the final development candidate under this strategic collaboration. CORPORATE UPDATES: In October 2024, C4T appointed Paige Mahaney, Ph.D., as the company’s chief scientific officer, succeeding Stew Fisher, Ph.D., who is retiring to pursue personal interests. Dr. Mahaney brings over 25 years of pharmaceutical executive leadership with multidisciplinary expertise in discovery research and development along with successfully building clinical portfolios across a wide range of disease indications and treatment modalities.In September 2024, C4T appointed Stephen Fawell, Ph.D., to the Board of Directors. Dr. Fawell brings decades of experience leading discovery and development strategies for global pharmaceutical companies. KEY UPCOMING MILESTONES Cemsidomide: Present updated dose escalation and expansion cohort data from the 50 µg M/W/F, 37.5 µg QD, 62.5 µg QD, and 75 µg QD dose levels in approximately 40 patients from the ongoing Phase 1/2 clinical trial with dexamethasone in R/R MM at the ASH Annual Meeting in December 2024.Present dose escalation data from the 25 µg M/W/F, 50 µg M/W/F, 37.5 µg QD, 62.5 µg QD, and 100 µg QD dose levels in approximately 25 patients from the ongoing monotherapy Phase 1/2 clinical trial in R/R NHL at the ASH Annual Meeting in December 2024.Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end. CFT1946: Initiate the Phase 1b dose escalation cohort evaluating CFT1946 in combination with trametinib in melanoma by year-end.Present data from multiple anticipated readouts in 2025, including: Full monotherapy CFT1946 dose escalation cohorts in BRAF V600 mutant solid tumors.Expansion cohorts evaluating CFT1946 as a monotherapy in melanoma.Phase 1b dose escalation cohort evaluating CFT1946 in combination with cetuximab in CRC. UPCOMING INVESTOR EVENTS: November 20, 2024, at 8 am GT: Management will participate in a fireside chat at the Jefferies London Healthcare conference taking place in London, UK.December 8, 2024: Management will host an investor call to discuss MM and NHL data from the ongoing Phase 1/2 trial of cemsidomide. THIRD QUARTER 2024 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2024 was $15.4 million, compared to $11.1 million for the third quarter of 2023. The increase in revenue was primarily due to recognition of an $8.0 million milestone from Biogen as well as $2.9 million of revenue recognized under our license and supply agreement with Betta, partially offset by reduced revenue from our agreement with Roche due to the completion of research activities in the third quarter of 2023 for a nominated target. Total revenue for the third quarter of 2024 reflects revenue recognized under our collaborations with Biogen, Betta, Merck, Merck KGaA, Darmstadt, Germany (MKDG) and Roche, and total revenue recognized in the third quarter of 2023 reflects revenue recognized under collaboration agreements with Biogen and Roche. Research and Development (R&D) Expense: R&D expense for the third quarter of 2024 was $31.8 million, compared to $28.3 million for the third quarter of 2023. The increase in R&D expense was primarily due to increased clinical trial expense as cemsidomide and CFT1946 continue to advance, partially offset by lower personnel costs. General and Administrative (G&A) Expense: G&A expense was $11.8 million for the third quarter of 2024, compared to $10.5 million for the third quarter of 2023. The increase in G&A expense was primarily attributable to higher personnel expense related to stock-based compensation. Net Loss and Net Loss per Share: Net loss for the third quarter of 2024 was $24.7 million, compared to $27.0 million for the third quarter of 2023. Net loss per share for the third quarter of 2024 was $0.35 compared to $0.55 for the third quarter of 2023. Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of September 30, 2024 were $284.4 million, compared to $295.7 million as of June 30, 2024, and $281.7 million as of December 31, 2023. The reduction in cash, cash equivalents and marketable securities during the third quarter was primarily the result of cash used in operating activities, partially offset by $10.3 million in net proceeds raised through our at-the-market (ATM) facility. C4T expects that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com. About CemsidomideCemsidomide is an orally bioavailable MonoDAC® degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726). About CFT1946CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585). Forward-Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts: Investors:Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com Media:Loraine SpreenSenior Director, Corporate Communications & Patient AdvocacyLSpreen@c4therapeutics.com Condensed Consolidated Balance Sheet Data(in thousands) (unaudited) (audited) September 30, 2024 December 31, 2023Cash, cash equivalents and marketable securities$284,400 $281,689Total assets 376,060 376,451Deferred revenue 49,417 37,285Total stockholders' equity 242,656 246,114 Condensed Consolidated Statements of Operations(in thousands, except share and per share amounts)(Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue from collaboration agreements$15,362 $11,072 $30,407 $17,495 Operating expenses: Research and development 31,838 28,347 78,124 87,315 General and administrative 11,768 10,533 31,751 31,784 Restructuring — — 2,437 — Total operating expenses 43,606 38,880 112,312 119,099 Loss from operations (28,244) (27,808) (81,905) (101,604)Other income (expense), net: Interest expense and amortization of long-term debt − related party — (167) — (1,373)Loss on early extinguishment of debt — (621) — (621)Interest and other income, net 3,578 2,562 11,162 6,862 Total other income, net 3,578 1,774 11,162 4,868 Loss before income taxes (24,666) (26,034) (70,743) (96,736)Income tax expense — (1,003) — (1,003)Net loss$(24,666) $(27,037) $(70,743) $(97,739)Net loss per share − basic and diluted$(0.35) $(0.55) $(1.03) $(1.99)Weighted-average shares outstanding − basic and diluted 69,627,190 49,212,126 68,958,938 49,103,351